These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2899962)

  • 1. Herpes simplex type 1 defective interfering particles do not affect the antiviral activity of acyclovir, foscarnet and adenine arabinoside.
    Harmenberg JG; Svensson LT
    Acta Virol; 1988 Mar; 32(2):153-5. PubMed ID: 2899962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of HSV clinical isolates to foscarnet and in vitro dual combination of foscarnet and acyclovir.
    Al-Samarai A; Kinghorn G; Potter C
    Chemioterapia; 1987 Jun; 6(2 Suppl):665-6. PubMed ID: 2855616
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
    Chatis PA; Miller CH; Schrager LE; Crumpacker CS
    N Engl J Med; 1989 Feb; 320(5):297-300. PubMed ID: 2536137
    [No Abstract]   [Full Text] [Related]  

  • 4. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
    Safrin S; Crumpacker C; Chatis P; Davis R; Hafner R; Rush J; Kessler HA; Landry B; Mills J
    N Engl J Med; 1991 Aug; 325(8):551-5. PubMed ID: 1649971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease.
    Charles SJ; Gray JJ
    Br J Ophthalmol; 1990 May; 74(5):286-8. PubMed ID: 2162190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced survival of ultraviolet-irradiated herpes simplex virus in cells exposed to antiviral agents.
    Schnipper LE; Lewin AA; Crumpacker CS
    Mutat Res; 1983 Feb; 116(2):65-72. PubMed ID: 6298618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds.
    Smith KO; Galloway KS; Ogilvie KK; Cheriyan UO
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1026-30. PubMed ID: 6297382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiviral activity of phosphonoacetic acid, phosphonopropionic acid, and trisodium phosphonoformate hexahydrate against herpesvirus hominis type 1 and type 2 in vitro].
    Thiel KD; Wutzler P; Sprössig M; Bertram D
    Pharmazie; 1982 Aug; 37(8):608. PubMed ID: 6292963
    [No Abstract]   [Full Text] [Related]  

  • 9. [Resistance of herpes simplex viruses to antiviral drugs].
    Scieux C; Bianchi A
    Pathol Biol (Paris); 1993 Feb; 41(2):172-7. PubMed ID: 8392160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds.
    Alenius S
    Arch Virol; 1980; 65(2):149-56. PubMed ID: 6252867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet.
    Reefschläger J; Wutzler P; Thiel KD; Herrmann G
    Pharm Res; 1987 Jun; 4(3):200-6. PubMed ID: 2855541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection.
    Spruance SL; Freeman DJ; Sheth NV
    Antimicrob Agents Chemother; 1986 Jul; 30(1):196-8. PubMed ID: 2944480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation.
    Ljungman P; Ellis MN; Hackman RC; Shepp DH; Meyers JD
    J Infect Dis; 1990 Jul; 162(1):244-8. PubMed ID: 2162368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus.
    Suzuki M; Okuda T; Shiraki K
    Antiviral Res; 2006 Nov; 72(2):157-61. PubMed ID: 16797734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
    Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
    J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplicity dependence and sensitivity of herpes simplex virus isolates to antiviral compounds.
    Harmenberg J; Wahren B; Sundqvist VA; Levén B
    J Antimicrob Chemother; 1985 May; 15(5):567-73. PubMed ID: 2989239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet.
    Pelosi E; Hicks KA; Sacks SL; Coen DM
    Adv Exp Med Biol; 1992; 312():151-8. PubMed ID: 1325102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined interaction of antiherpes substances and interferon beta on the multiplication of herpes simplex virus.
    Janz C; Wigand R
    Arch Virol; 1982; 73(2):135-43. PubMed ID: 6184033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.
    Safrin S; Assaykeen T; Follansbee S; Mills J
    J Infect Dis; 1990 Jun; 161(6):1078-84. PubMed ID: 2161035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation.
    Iino T; Gondo H; Ohno Y; Minagawa H; Iwasaki H; Maruyama T; Nakashima H; Niho Y
    Bone Marrow Transplant; 1996 Dec; 18(6):1185-8. PubMed ID: 8971394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.